Lipid nanoparticle licensing and collaboration agreements for Genevant Sciences

Represented Genevant Sciences in negotiating and drafting several license and collaboration agreements for Genevant’s lipid nanoparticle technology, including agreements with Gritstone Oncology relating to COVID-19 and BioNTech relating to development of mRNA therapeutics for rare diseases.